伏诺拉生在幽门螺杆菌根除中的应用  

Role of Vonoprazan in Helicobacter pylori eradication therapy

作　　者：高雯雯[1] 张翔[1] 王倩 尹雁惠 王潞 Gao Wenwen;Zhang Xiang;Wang Qian;Yin Yanhui;Wang Lu(Clinical Pharmacy Department,Jinan Central Hospital,Jinan 250013,China)

机构地区：[1]济南市中心医院临床药学科,250013

出　　处：《国际医药卫生导报》2021年第20期3150-3153,共4页International Medicine and Health Guidance News

基　　金：山东省医学会临床科研专项资金-临床药学应用研究项目(YXHZX019);济南市卫生健康委员会科技发展计划项目(2018-2-01)。

摘　　要：幽门螺杆菌(Helicobacterpylori,Hp)感染与胃炎、消化性溃疡、胃恶性肿瘤等疾病密切相关,因此各国强烈建议根除Hp,以降低消化性溃疡复发、预防胃癌的发生。然而,由于Hp对抗菌药物耐药性增加以及胃酸分泌抑制的不足,以质子泵抑制剂为基础的治疗方案的根除率逐渐下降。伏诺拉生是一种钾离子竞争性拮抗剂,因其强烈而持久的抑制胃酸分泌及良好的根除Hp的疗效引起临床广泛的关注。因此,本文将对伏诺拉生的抑酸特点及其在根除Hp中的疗效和安全性进行综述。Helicobacter pylori(Hp)infection is closely associated with gastritis,peptic ulcer,and gastric malignancies.Hp eradication is strongly recommended for lowering peptic ulcer recurrence and preventing gastric cancer.However,the eradication rate of Hp by using proton pump inhibitor-based regiments has decreased mostly due to antibiotic resistance and insufficient suppression on gastric acid.Vonoprazan,as a potassium-competitive acid blocker,has gained clinical attention due to long-lasting inhibition on gastric acid secretion.In this review,we discuss the acid suppression characteristics of Vonoprazan and its efficacy and safety in Hp eradication.

关 键 词：伏诺拉生 钾离子竞争性拮抗剂 质子泵抑制剂 幽门螺旋杆菌 

分 类 号：R573[医药卫生—消化系统]